Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study
Ghassan K. Abou-Alfa, Teresa Macarulla, Milind M. Javle, Robin K. Kelley, Sam J. Lubner, Jorge Adeva, James M. Cleary, Daniel V. Catenacci, Mitesh J. Borad, John Bridgewater, William P. Harris, Adrian G. Murphy, Do Youn Oh, Jonathan Whisenant, Maeve A. Lowery, Lipika Goyal, Rachna T. Shroff, Anthony B. El-Khoueiry, Bin Fan, Bin WuChristina X. Chamberlain, Liewen Jiang, Camelia Gliser, Shuchi S. Pandya, Juan W. Valle, Andrew X. Zhu
Dive into the research topics of 'Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study'. Together they form a unique fingerprint.